Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 5:14 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,943 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Context 2 Clear all
Completed Not applicable Interventional Results available

Development of Technologies to Increase In-Seat Movement to Prevent Sitting-Acquired Pressure Injuries in Wheelchair Users

NCT04934137
View directory record Official record
Conditions
Pressure Ulcer, Pressure Injury, Wheelchair
Interventions
Sensoria, AW-Shift
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Atlanta, Georgia • Minneapolis, Minnesota • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Nov 8, 2026, 5:14 PM EST
Completed Phase 2 Interventional Results available

Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

NCT04068181
View directory record Official record
Conditions
Melanoma
Interventions
Talimogene laherparepvec, Pembrolizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Santa Barbara, California • Newark, Delaware • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2025 · Synced Nov 8, 2026, 5:14 PM EST
Completed Phase 1 Interventional

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

NCT04584112
View directory record Official record
Conditions
Triple-Negative Breast Cancer
Interventions
Tiragolumab, Atezolizumab, Nab-paclitaxel, Carboplatin, Doxorubicin, Cyclophosphamide, Granulocyte colony-stimulating factor (G-CSF), Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Birmingham, Alabama • Chicago, Illinois • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Nov 8, 2026, 5:14 PM EST
Completed No phase listed Observational Results available

Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.

NCT04460911
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 11, 2024 · Synced Nov 8, 2026, 5:14 PM EST
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Bone Marrow Derived Stem Cells Mobilization for Treatment of Abnormal Endometrium

NCT05343572
View directory record Official record
Conditions
Asherman Syndrome, Atrophic Endometrium, Recurrent Implantation Failure
Interventions
Plerixafor
Drug
Lead sponsor
Hugh Taylor
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Orange, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Nov 8, 2026, 5:14 PM EST
Completed Not applicable Interventional Results available

TENS Treatment for Bedwetting

NCT04313192
View directory record Official record
Conditions
Nocturnal Enuresis, Bed Wetting
Interventions
pulse rate of 2 Hz, pulse rate of 10 Hz, pulse rate of 150 Hz
Device
Lead sponsor
Albany Medical College
Other
Eligibility
5 Years to 18 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Nov 8, 2026, 5:14 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2 for 26 Weeks

NCT02396381
View directory record Official record
Conditions
Smoking
Interventions
THS 2.2, CC
Other
Lead sponsor
Philip Morris Products S.A.
Industry
Eligibility
30 Years and older
Enrollment
1,039 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
19
States / cities
Tempe, Arizona • Clearwater, Florida • Daytona Beach, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Nov 8, 2026, 5:14 PM EST
Completed Phase 2 Interventional Results available

Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies

NCT01974765
View directory record Official record
Conditions
Advanced Epithelial Ovarian, Recurrent Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Carcinoma
Interventions
Enzalutamide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Nov 8, 2026, 5:14 PM EST
Completed Not applicable Interventional

Resilience-Based Diabetes Self-Management Education (RB-DSME) for African Americans

NCT04282395
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Resilience-Based Diabetes Self-Management Education, Standard Diabetes Self-Management Education
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Nov 8, 2026, 5:14 PM EST
Not yet recruiting Not applicable Interventional

ED PLWD/Care Partner Text Messaging

NCT07423871
View directory record Official record
Conditions
Dementia, Caregiver, Emergency Department, Mobile Health Technology (mHealth)
Interventions
CAPTURE Text Message Care Transition Support
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Nov 8, 2026, 5:14 PM EST
Completed Not applicable Interventional

Effect of a Low-Calorie Diet and/or Exercise Program on Risk Factors for Developing Breast Cancer in Overweight or Obese Postmenopausal Women

NCT00470119
View directory record Official record
Conditions
Breast Cancer, Obesity, Weight Changes
Interventions
behavioral dietary intervention, Exercise intervention
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
50 Years to 75 Years · Female only
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Nov 8, 2026, 5:14 PM EST
Active, not recruiting Phase 2 Interventional

Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.

NCT06087263
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Regorafenib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Nov 8, 2026, 5:14 PM EST
Terminated Phase 3 Interventional Results available

Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH

NCT02725372
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Inhaled Nitric Oxide 75 mcg/kg IBW/hr, Placebo
Drug
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
18 Years to 85 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
37
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Nov 8, 2026, 5:14 PM EST
Terminated Not applicable Interventional Results available

Use of a Non-Invasive Brainstem Neuromodulation Device to Improve Neurovascular Status in Parkinson's Disease

NCT04598828
View directory record Official record
Conditions
Parkinson Disease
Interventions
Non-invasive brainstem stimulation
Device
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
21 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Nov 8, 2026, 5:14 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Project HOME: Home-Based Treatment Options and Mechanisms for Eating Disorders

NCT05184556
View directory record Official record
Conditions
Anorexia Nervosa, Eating Disorders
Interventions
Family-based treatment (FBT), Integrative family therapy
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years to 18 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Pawtucket, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Nov 8, 2026, 5:14 PM EST
Recruiting Phase 1Phase 2 Interventional

Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma

NCT07136181
View directory record Official record
Conditions
Metastatic Uveal Melanoma, Uveal Melanoma, Metastatic, Uveal Melanoma, Recurrent, Eye Cancer, Intraocular Melanoma, Eye Cancer
Interventions
NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers.
Drug
Lead sponsor
Novelwise Pharmaceutical Corporation
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
3
States / cities
Scottsdale, Arizona • Denver, Colorado • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Nov 8, 2026, 5:14 PM EST
Completed Not applicable Interventional

Enhancing Resilience in Young Stroke Survivors With Res-ET

NCT05348044
View directory record Official record
Conditions
Resilience, Stroke
Interventions
Res-ET intervention
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Nov 8, 2026, 5:14 PM EST
Completed Not applicable Interventional

Testing the Effectiveness of Mainstream Management Tools to Increase Organizational Commitment and Job Satisfaction and Decrease Turnover Among Peer Providers

NCT04398407
View directory record Official record
Conditions
Mental Health, Work Related Stress
Interventions
Coaching and Advancement for Peer Providers (CAPP)
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Nov 8, 2026, 5:14 PM EST
Recruiting Not applicable Interventional

Development of a Recovery Oriented Treatment for Post-Acute Suicidal Episode (PASE) Veterans

NCT04731519
View directory record Official record
Conditions
Suicide
Interventions
Continuous Identity Cognitive Therapy (CI-CT), General Health Education
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Nov 8, 2026, 5:14 PM EST
Terminated Phase 2 Interventional Results available

Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose

NCT04715230
View directory record Official record
Conditions
Methamphetamine Intoxication (Disorder)
Interventions
IXT-m200, Lorazepam, Haloperidol
Biological · Drug
Lead sponsor
InterveXion Therapeutics, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Little Rock, Arkansas • Albuquerque, New Mexico • Everett, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Nov 8, 2026, 5:14 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Immunological Responses of COVID-19 Vaccination

NCT05238467
View directory record Official record
Conditions
Cancer; Chemotherapy
Interventions
COVID antibody titers in the blood
Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Nov 8, 2026, 5:14 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Interventions for Communication in Autism Network

NCT01018407
View directory record Official record
Conditions
Autism
Interventions
Discrete Trial Training, Interpersonal Developmental Approach
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
33 Months to 54 Months
Enrollment
192 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
3
States / cities
Los Angeles, California • Baltimore, Maryland • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 14, 2024 · Synced Nov 8, 2026, 5:14 PM EST
Completed Not applicable Interventional Results available

Efficacy and Safety of Cranial Electrical Stimulation (CES) for Major Depressive Disorder (MDD)

NCT01325532
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Active CES, Sham CES
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Nov 8, 2026, 5:14 PM EST
Completed Not applicable Interventional Results available

Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States

NCT02395536
View directory record Official record
Conditions
Arrhythmia
Interventions
office setting, hosptial setting
Other
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years to 99 Years
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
27
States / cities
La Jolla, California • Mission Viejo, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Nov 8, 2026, 5:14 PM EST